Science brief
Intracellular Drug Delivery and European Research Funding
Israeli scientists penetrate cellular membranes to target internal disease proteins while local university labs secure ₪57 million in EU research grants.
Science
Israeli university researchers solved the intracellular antibody barrier — opening 80% of previously untreatable target proteins to biological drug therapy.
BackgroundOver 80% of disease-causing human proteins reside inside cell structures, rendering them inaccessible to conventional antibody therapies. Delivering biological treatments past outer cell walls has remained one of molecular medicine's most stubborn technical hurdles.
- The research team developed a temporary synthetic coating called SL4 combined with lipid nanoparticles to transport intact, functional antibodies past cell walls.
- In lab models of Parkinson's disease, the delivery system cleared pathological alpha-synuclein protein aggregates inside nerve cells without damaging host tissue.
- The masking technique also demonstrated therapeutic efficacy in acute inflammatory lung injury models while preserving long-term antibody structural stability, opening broader applications across oncology and neurology.
Science
Israeli neuroscience research proves tau protein ruins deep sleep memory consolidation — establishing non-REM sleep quality as a direct target for Alzheimer's treatment.
BackgroundNon-REM deep sleep acts as a neurological filing system, transferring daily experiences into long-term memory storage within the human brain. Alzheimer's disease is characterized by toxic accumulations of amyloid-beta and tau proteins that destroy neural pathways over time.
- Researchers discovered that tau protein accumulation in frontal brain regions directly degrades slow-wave brain synchrony during deep sleep cycles.
- Disrupted sleep waves prevent the brain from locking in daily episodic memories, accelerating cognitive decline in preclinical patient groups.
- The mechanistic finding establishes measurable slow-wave electroencephalogram biomarkers for clinical trials testing sleep-restoration drugs to slow Alzheimer's progression, shifting focus toward preventative sleep therapies.
Science
Eleven European Research Council grants inject critical non-governmental funding into Israeli university labs — preserving top-tier research capacity amid tightening domestic academic budgets.
BackgroundThe European Research Council awards Starting Grants to exceptional young academics across Horizon Europe member states to establish independent laboratory facilities. Israeli research departments rely heavily on European grants to fund physical lab infrastructure and international doctoral research positions.
- Tel Aviv University led Israeli institutions with 5 individual grant awards, followed by Technion and Bar-Ilan University with 2 grants each.
- Each award provides up to ₪5.25 million ($1.7M) in direct laboratory funding, securing physical equipment and research personnel through 2031.
- The grants preserve Israel's academic footing in Horizon Europe despite recent declines in total European funding allocations to domestic research centers.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
